Increased Mortality and Comorbidity Associated With Leber's Hereditary Optic Neuropathy:A Nationwide Cohort Study by Vestergaard, Nanna et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Increased Mortality and Comorbidity Associated With Leber's Hereditary Optic
Neuropathy
Vestergaard, Nanna; Rosenberg, Thomas; Torp-Pedersen, Christian; Vorum, Henrik;
Andersen, Carl U.; Aasbjerg, Kristian
Published in:
Investigative Ophthalmology & Visual Science
DOI:
10.1167/iovs.17-21990
Publication date:
2017
Document license:
CC BY-NC-ND
Citation for published version (APA):
Vestergaard, N., Rosenberg, T., Torp-Pedersen, C., Vorum, H., Andersen, C. U., & Aasbjerg, K. (2017).
Increased Mortality and Comorbidity Associated With Leber's Hereditary Optic Neuropathy: A Nationwide Cohort
Study. Investigative Ophthalmology & Visual Science, 58(11), 4586-4592. https://doi.org/10.1167/iovs.17-21990
Download date: 03. Feb. 2020
Clinical and Epidemiologic Research
Increased Mortality and Comorbidity Associated With
Leber’s Hereditary Optic Neuropathy: A Nationwide
Cohort Study
Nanna Vestergaard,1 Thomas Rosenberg,2,3 Christian Torp-Pedersen,4 Henrik Vorum,5 Carl U.
Andersen,5 and Kristian Aasbjerg4,5
1Faculty of Medicine, Aalborg University, Aalborg, Denmark
2Department of Ophthalmology, Rigshospitalet-Glostrup-Kennedy, Glostrup, Denmark
3Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
4Department of Epidemiology, Aalborg University Hospital, Aalborg, Denmark
5Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark
Correspondence: Nanna Vester-
gaard, The Faculty of Medicine,
Aalborg University, Niels Jernes Vej
10, 9220 Aalborg East, Denmark;
nanna.vestergaard@rn.dk.
Submitted: April 3, 2017
Accepted: August 8, 2017
Citation: Vestergaard N, Rosenberg T,
Torp-Pedersen C, Vorum H, Andersen
CU, Aasbjerg K. Increased mortality
and comorbidity associated with Leb-
er’s hereditary optic neuropathy: a
nationwide cohort study. Invest Oph-
thalmol Vis Sci. 2017;58:4586–4592.
DOI:10.1167/iovs.17-21990
PURPOSE. Leber’s hereditary optic neuropathy (LHON) is a mitochondrial genetic disease in
which optic neuropathy is considered a key feature. Several other manifestations of LHON
have been reported; however, only little is known of their incidence and the life expectancy
in LHON patients.
METHODS. This study, based on Danish nationwide health registries, included 141 patients
diagnosed with LHON and 297 unaffected family members in the maternal line. The incidence
of comorbidities and mortality for patients with LHON and unaffected family members was
compared with that in the general population.
RESULTS. Having LHON was associated with an almost 2-fold risk of mortality with a rate ratio
(RR) of 1.95 (95% confidence interval [CI]: 1.47–2.59; P < 0.001). The incidence of several
diseases was increased for LHON patients, but not for family members. The incidence of
stroke was 5.73 per 1000 patient-years for LHON patients compared to 2.33 for the general
population, and the RR was 2.38 (95% CI: 1.58–3.58; P < 0.001). The incidence of
demyelinating disorders was 2.24 compared to 0.21 for the general population; RR was 12.89
(95% CI: 6.70–24.77; P < 0.001). A 4-fold risk of dementia was seen for LHON patients (RR:
4.26, 95% CI: 1.91–9.48; P < 0.001), incidence 1.45 for LHON and 0.37 for the general
population. Moreover, LHON patients had an increased risk of epilepsy, atherosclerosis, nerve
symptoms, neuropathy, and alcohol-related disorders.
CONCLUSIONS. The manifestation of LHON was associated with increased mortality and
increased incidence of several disorders including stroke, demyelinating disorder, dementia,
and epilepsy.
Keywords: Leber’s hereditary optic neuropathy, mitochondria, optic neuropathy, mortality,
comorbidities
Leber’s hereditary optic neuropathy (LHON) is a mitochon-drial genetic disease resulting in acute or subacute loss of
vision, affecting mostly men in their second or third decade.1
As a consequence, LHON has a strong negative impact on
quality of life.2 It results from a point mutation in the
mitochondrial DNA and is therefore maternally inherited.
Although several point mutations have been shown to
potentially cause LHON, more than 90% of cases are caused
by one of three primary mutations (G3460A, G11778A, or
T14484C).1 LHON is generally accepted as the most prevalent
mitochondrial disease,3 with an average European prevalence
of 1:45,000.4 LHON has an incomplete penetrance,5 which is
assumed to be caused by both genetic and environment
factors.6
The loss of vision observed in LHON is caused by
degeneration of the retinal ganglion cells. However, the
biochemical mechanism is largely unknown. The mutations in
mitochondrial DNA alter the function of the mitochondria
leading to multiple possible causative effects, including
decreased ATP production as well as increased production of
reactive oxygen species.1,7 The high metabolic demands of the
retinal ganglion cells are thought to make them especially
vulnerable to decreased mitochondrial function,8 and in
consequence other high-energy tissues may be affected,
possibly subclinically.
Although optic neuropathy is considered characteristic for
the disease, several other manifestations of LHON have been
reported, including neurologic and cardiac abnormalities,
sometimes referred to as Leber’s plus.9–12 Unfortunately, these
studies tend to include only small cohorts and investigate a
limited number of additional manifestations. Likewise, few
studies on mortality have been published. In fact, little is
known of life expectancy and cause of death in LHON patients.
With a thorough characterization of a large cohort, the
present study aimed to investigate the overall survival and
comorbidities of individuals affected by LHON and unaffected
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family members, whether obligate or proven to harbor a
pathogenic mitochondrial mutation or not, compared to
healthy controls.
METHODS
This registry-based study comprised data from nationwide
Danish health registries. The incidence of comorbidities and
mortality for patients with LHON and healthy family members
was compared to that of the general population.
Registers
Since 1968, every Danish citizen has been assigned a unique,
permanent civil registration number by the Civil Population
Register, making linkage of individuals among nationwide
registries possible.
The national Danish Registry of Families with Hereditary
Eye Disorders includes patients and families with any
diagnosed genetic disorder affecting the eye. The registry
was founded in 1985 and is curated at the Department of
Ophthalmology, Rigshospitalet, University of Copenhagen, the
former National Eye Clinic for the Visually Impaired. The
register is considered almost complete due to a highly
centralized national molecular diagnostic and rehabilitation
service for the whole Danish population.
The Danish National Hospital Register holds information of
all hospital admissions in Denmark, including date of admission
and all relevant diagnoses at discharge classified according to
the International Classification of Diseases 8th and 10th
revisions (ICD-8 and ICD-10) since 1976. Combined, these
registries provide information on all diagnoses given at a
hospital for all patients known with LHON and their relatives.
Study Population
The study cohort was identified in the Danish Family Registry.
The clinical diagnosis is based on symptoms and signs
characteristic for LHON, the family history, and since 1989
also molecular genetic analyses. As a result, a full characteriza-
tion of the nation-based LHON cohort including diagnosed
cases and family members was obtained.13
All identified patients and their family members assigned a
Civil Registration number are included. Individuals were
registered as either (1) subjects with LHON or (2) their
brothers and sisters and first-degree relatives in the ascending
maternal line without reported manifest LHON. More distant
relatives in side branches of the genealogy without any
manifestation of LHON are not included. As controls, the
general Danish population apart from LHON patients and their
family members was included. Hence, the study population
comprised individuals included in one of three groups: (1)
LHON, (2) family members, (3) general population. All the
involved individuals were included and started follow-up at the
age of 30, as the age of onset for LHON was not known for all
LHON patients. Inclusion started at year 1960 and continued
onward. Prior to the analyses, individuals with an endpoint
diagnosis before inclusion were excluded. Individuals were
followed up until the first occurrence of one of the following:
death, emigration, end of follow-up (December, 31, 2014), or
presence of one of the endpoint diseases listed below. Vital
status was obtained from the Central Population Register.
Outcomes and Endpoints
Diseases previously described to coexist with one of the three
primary LHON mutations were identified through a systematic
literature search in PubMed and Embase using the search term
LHON and nine synonyms, resulting in 2169 articles after
duplicates were removed. After screening for articles on
comorbidities, a total of 160 articles proved relevant and
ultimately resulted in a list of the diseases previously published
as coexisting with LHON (see Supplementary Table S1). From
this list, diseases with no available data in the registries or with a
numerically insignificant number of observations among LHON
patients and family members (<7) were excluded. Included
diagnoses were classified according to ICD-10. Included
comorbidities were grouped into diagnostic categories to
increase the power of the study. Diagnostic categories are
presented in Table 1 with matching ICD-8 and ICD-10 codes.
Statistics
The rate ratios (RR) of mortality and comorbidities among
individuals with LHON or family members compared to the
general population were analyzed via a time-dependent
approach by using multivariate Poisson regression models.14
Separate Poisson regression analyses were performed for each
comorbidity. All individuals entered the study at the age of 30,
starting from January 1960. Individuals were followed up until
the appearance of a comorbidity of interest, death, or the end
of 2014. For Poisson regression, all individuals were split into
separate records according to two time scales using the Lexis
macro (http://publicifsv.sund.ku.dk/~pka/epidata/Lexis.sas; in
the public domain; last accessed February 20, 2017). Calendar
time was split by the years 1985, 1995, 2000, and 2005. Age
was split according to 5-year increments. Variables were
determined at the start of each time band for analyses. Testing
showed that shorter time bands did not change the results.
Poisson regression was performed with PROC GENMOD from
the SAS Institute (Cary, NC, USA). From inclusion, individuals
with LHON contributed with person years to disease exposure
time for LHON patients while unaffected family members con-
tributed to exposure time for unaffected family members. RR
were expressed with 95% confidence interval (95% CI). A P
value less than 0.05 was considered significant.
Descriptive data were reported as percentages. For the
comorbidities and mortality, incidence ratios were expressed
as the number of events per 1000 patient-years.
TABLE 1. List of Diagnostic Categories Included as Endpoints in the
Study, With Matching ICD-8 and ICD-10 Codes
Diagnostic Category ICD-8 ICD-10
Heart disease
All heart disease 393–399, 40–45 DI
Atherosclerosis 440 DI70
Arrhythmia DI44, DI45, DI47–49
Ischemic heart disease 411–414 DI20–25
Heart failure 425, 4270–71 DI42, DI50, DI110
Stroke 433–435 DI60–64, DG45–46
Neurologic disorders
Demyelination disorders 340–41 DG35–37
Neuropathy DG5–6
Nerve symptoms DR20, DR25–27, DR29
Epilepsy 345 DG40–41
Migraine and other
headache disorder
346 DG43–44
Alcohol-related disorders DF10
Dementia 290 DF00–DF03
Deafness 389 DH90–91
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Overall mortality was expressed by Kaplan-Meier estimates.
Comorbidities were expressed as cumulative incidence ac-
counting for competing risks of death from other causes.
All statistical analyses were performed using Statistical
Analysis System version 9.4 and R Statistics version 3.3.0 (R
Foundation for Statistical Computing, Vienna, Austria; http://
www.R-project.org/; in the public domain).
Ethical Considerations
In Denmark, registry-based studies do not require ethical
approval or patient consent. The Danish Data Protection
Agency approved the design of the study (approval no. 2008-
58-028), and the authors adhered to the tenets of the
Declaration of Helsinki.
RESULTS
From the national registries, 236 patients with LHON and 590
unaffected family members were identified. After including
only individuals at 30 years of age no earlier than 1960, the
study population comprised 141 LHON patients, 297 unaf-
fected family members, and 3,753,935 individuals from the
general population. The male/female distributions are listed
in Table 2.
For a subset of the comorbidities, cumulative incidences
accounting for competing risk of death by other causes are
illustrated in Figure 1 together with the 1-Kaplan-Meier curves
for mortality. The incidence rates (IR), RR, and P values are
presented in Figure 2. The RR are adjusted for age, calendar
year, and sex.
The incidence of heart diseases for LHON patients was
20.54 compared to 14.35 per 1000 patient-years in the general
population with a RR of 1.44 (95% CI: 1.14–1.81; P ¼ 0.002).
Atherosclerosis and stroke among LHON patients had a RR of
2.2 (95% CI: 1.10–4.40; P ¼ 0.026) and 2.38 (95% CI: 1.58–
3.58; P < 0.001) respectively.
The incidence of a number of neurologic diseases was
higher among LHON patients; see Figure 2. The RR for
dementia was 4.26 (95% CI: 1.91–9.48; P < 0.001), epilepsy RR
2.99 (95% CI: 1.56–5.75; P¼ 0.001), nerve symptoms RR 3.13
(95% CI: 1.78–5.51, P < 0.001), and neuropathy RR 1.75 (95%
CI: 1.01–3.01; P ¼ 0.044). The highest-incidence RR was for
demyelinating disorders, 12.89 (95% CI: 6.70–24.77; P <
0.001).
The incidence of alcohol-related disorders was 11.30 for
LHON patients compared to 1.41 for the general population.
The RR was 7.53 (95% CI: 5.59–10.16; P < 0.001).
Having LHON was associated with an increased risk of
death RR 1.95 (95% CI: 1.47–2.59; P < 0.001); see Figure 2.
The risk of death for family members did not differ significantly
from the general population.
No significant increases were observed for ischemic heart
disease, heart failure, arrhythmia, migraine, or deafness. For all
the comorbidities, no differences among unaffected family
members and the general population were observed
DISCUSSION
It is widely accepted that mitochondrial diseases predominant-
ly manifest in tissues/organs with high energy requirements,
such as the central and peripheral nervous system, eyes, inner
ears, and heart.15 Our findings add to the existing knowledge
by demonstrating that the manifestation of LHON is associated
with a statistically increased risk of certain diseases of the
nervous system and heart. However, the causality is uncertain.
Furthermore, the present study indicates increased alcohol
consumption or susceptibility to alcohol-related disorders
among LHON patients, which could potentially contribute to
the increased risk of other diseases.
It is noteworthy that unaffected family members did not
show an increased risk of the disorders included in the study.
This might suggest either common pathophysiological etiology
for the manifestation of LHON and associated comorbidities, or
that having LHON itself implies an increased risk of accompa-
nying diseases.
Most of the existing literature on cardiovascular diseases
and LHON concerns cardiomyopathy and arrhythmia. This
study did not find the incidence of hospital-diagnosed
arrhythmia or heart failure (including cardiomyopathy, see
Table 1) to be increased among LHON patients. In contrast,
this study found an increased incidence of atherosclerosis for
LHON patients, which in turn might increase the risk of
hypertension. Thus in female carriers without LHON, the
mt14484 mutation has been shown to be a potential cause of
essential hypertension.16 To our knowledge, few data exist on
vascular diseases in LHON patients, although they have been
found to have increased aortic stiffness.17 With regard to
stroke, a correlation to secondary LHON mutations has been
reported.18 The results of this study demonstrated a signifi-
cantly higher risk of stroke among LHON patients, suggesting
that there might be an association with primary LHON
mutations.
It is well known that neurologic disorders are present in
many LHON patients.9 Neuropathy has previously been found
in a small cohort of LHON patients.19 However, another study
found only 1 in 104 LHON patients to have neuropathy.20
Supporting these findings, we found an association between
LHON patients and an increased prevalence of neurologic
symptoms and neuropathy. This correlates with the existing
literature reporting a spectrum of neurologic symptoms among
LHON patients.
Similarly, unaffected family members of LHON patients have
previously been associated with an increased prevalence of
neurologic abnormalities. This association was correlated to
how closely they were related to the LHON patient.21 In the
present study, unaffected family members were not associated
with an increased incidence of neurologic symptoms or
neuropathy. This could be caused by a lack of subdivision
according to closeness of the relation to the LHON patient.
The neural abnormalities observed in some LHON patients
have also been suggested to involve the central auditory
pathways. However, to our knowledge only few studies have
investigated this and with conflicting results.22–24 Our study
did not find an increased risk of deafness for LHON patients.
Few studies on a limited number of families have reported
coexistence of migraine and LHON.25,26 In this study no
association between LHON and migraine was found.
TABLE 2. Characteristics of the Study Population
Characteristic
LHON
141
Family
Members
297
General
Population
3,753,935
Males (%) 103 (73) 122 (41) 1,896,503 (51)
Mutation (%)
11778G>A 103 (73) 168 (57) –
3460G>A 20 (14) 67 (23) –
14484T>C 12 (9) 33 (11) –
No mutation found 6 (4) 29 (9) –
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FIGURE 1. Cumulative incidences for comorbidities accounting for competing risk of death by other causes, and 1-Kaplan-Meier curves for overall
mortality. The cumulative incidences are the risk of having the disease if being at risk (alive). For all the above comorbidities, rate ratios were
significant for LHON patients but not for family members. TIA, transient ischemic attack.
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Regarding dementia, the pathology of Alzheimer’s disease
and Parkinson’s disease has been proposed to include
mitochondrial DNA variations27; however, only sparse data
have linked LHON and dementia (see Supplementary Table S1).
Our study adds to the existing evidence that there might be an
association between dementia in general and mitochondrial
DNA variations, more specifically LHON.
The relation between multiple sclerosis (MS) or MS-like
disease and LHON has attracted special attention in the
literature as it has previously been shown that primary LHON
mutations increase the risk of MS.28 This was confirmed by the
present study. A recent study showed that cerebral magnetic
resonance imaging (MRI) in MS-like LHON and MS was alike,
providing support for a common pathophysiological mecha-
nism.29 The pathophysiology of MS is still not fully understood,
but mitochondrial mutations are presumed to play a role in the
susceptibility to the disease, though studies on potential
responsible genes are controversial.30 Several studies in
patients with MS have failed to demonstrate the primary
LHON mutations among these.31–33 In conclusion, it would
seem that LHON patients have increased risk of an MS-like
disease, but that primary LHON mutations do not play a role in
the majority of cases of MS.
The unknown burden of associated comorbidities could
potentially negatively influence quality of life throughout the
entire life span of individuals with LHON-associated muta-
tions.2 Alcohol consumption has previously been shown to be
higher among some patients with LHON.34 This study found an
FIGURE 2. Incidences and rate ratios for comorbidities and mortality among LHON patients and unaffected family members compared to the
general Danish population. RR were calculated by Poisson regression and adjusted for sex, age, and calendar year. Count, number of events; RR, rate
ratios; 95% CI, 95% confidence interval.
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increased risk of alcohol-related disorders such as alcohol
abuse and dependence. It is uncertain whether alcohol
consumption increases the risk of developing LHON or if
having LHON evokes higher alcohol consumption.
While a recent study investigated the cause of death among
patients with mitochondrial diseases,35 there has been only
limited evidence on life expectancy among LHON patients. In
this study, increased mortality was found for LHON patients.
Even though the causes remain unknown, the present study
provides evidence of increased incidence of a number of
comorbidities potentially contributing to increased mortality.
Strengths and Limitations
The multivariate analyses on incidence of comorbidities and
mortality were adjusted for age, calendar year, and sex.
Retrospective cohort studies based on registries have some
built-in limitations; no data on smoking habits or body mass
index were available, and hence the analysis could not be
controlled for these confounding factors.
Additionally, the diagnosis of comorbidities relies on
registered diagnosis at a hospital. Though the registries have
been shown to be accurate regarding some diseases,36 the
sensitivity for other diagnoses could be questioned, especially
coding on symptoms with no specific diagnostic criteria. For
instance, alcohol-related conditions were included as an
approximation for high alcohol consumption. However, there
may be a proportion of patients with excessive alcohol con-
sumption but without a hospital diagnosis. The same is true for
nerve-related symptoms. As the diagnosis greatly relies on
reporting from patients, it could be speculated that having a
chronic disease, such as LHON, might affect the patient’s
likelihood of contacting a doctor and report other symptoms.
This could potentially bias the results. In addition, the register
for diagnoses holds only for information from year 1976 onward.
Furthermore, all individuals were included at age 30, and
patients with LHON were regarded as such at inclusion
irrespective of actual age at onset. The median age at onset
in Denmark has previously been shown to be 25 for males and
33 for females.13 Therefore, individuals most likely at age 30
will be influenced by the genetic or environmental factors
determining the penetrance for LHON mutations. All family
members were relatives in the ascending female line and
therefore probably harbored the mutation, however possibly
with individual differences in mutational load, which was not
accounted for.
Finally, this study included only disorders following hospital
admission and therefore could not uncover the prevalence and
risk of subclinically or less severe symptoms not resulting in
hospital diagnoses. Moreover, the causality between LHON and
other manifestations is still unsolved.
CONCLUSIONS
In this population-based study including 141 LHON patients,
297 unaffected family members, and the entire Danish
population as a reference, the manifestation of LHON was
association with an increased risk of heart diseases in general,
atherosclerosis, stroke, dementia, epilepsy, demyelinating disor-
ders, nerve symptoms, neuropathy, and alcohol-related disor-
ders. Moreover, the risk of death was almost doubled for LHON
patients compared to the general Danish population (RR 1.95).
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